C. Arrigoni

Assessment of QT liabilities in drug development

P. Crivori, C. Arrigoni, C. Arrigoni, 2006, Cell Biology and Toxicology.

Selectivity enhancement induced by substitution of non-natural analogues of arginine and lysine in arginine-based thrombin inhibitors.

C. Arrigoni, K. Kokko, T. Dix, 2001, Bioorganic & medicinal chemistry letters.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Paola Storici, Cristina Alli, Maurizio Rocchetti, 2007, Molecular Cancer Therapeutics.

Cardiovascular Liabilities of Drugs: Regulatory Aspects

C. Arrigoni, 2010 .

Identification of patients at high risk for hypocalcemia after total thyroidectomy

B. Gibelli, N. Tradati, C. Arrigoni, 2011, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.

C. Caccia, M. Varasi, R. Mcarthur, 1997, Journal of medicinal chemistry.

Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.

S. Marchini, M. Ciomei, F. Fiorentini, 2001, Cancer research.

Cytoprotective and antisecretory effects of 11-deoxy-13,14-didehydro-16(s)-methyl PGE2 methylester (FCE 20700).

F. Faustini, C. Arrigoni, R. Ceserani, 1984, Prostaglandins, leukotrienes, and medicine.

Pharmacological and Toxicological Aspects of 4-Demethoxy-3 *-deamino-3 *-aziridinyl-4 *-methylsulphonyl-daunorubicin ( PNU-159548 ) : A Novel Antineoplastic Agent 1

S. Marchini, M. Ciomei, F. Fiorentini, 2001 .

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

W. Evering, S. Turnquist, A. Terron, 2008, Toxicologic pathology.

PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential

A. Terron, D. Moneta, M. Brughera, 2001, Cancer Chemotherapy and Pharmacology.